Medical device company Paragon 28 Inc (NYSE:FNA) said on Friday that it has priced its initial public offering of 7,812,500 shares of its common stock.
All of the shares are being offered and sold by the company at a public offering price of USD16.00 per share for total gross proceeds of USD125.0m, before deducting underwriting discounts and commissions and estimated offering expenses.
The company has provided the underwriters with a 30-day option to purchase up to another 1,171,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
For the offering, BofA Securities and Piper Sandler are acting as joint lead book-running managers. Canaccord Genuity is acting as a lead manager. The offering is expected to close on 19 October 2021, subject to the satisfaction of customary closing conditions.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project